Lifecore Biomedical Inc. reports a Return on Equity (ROE) of -196.78%.

What is LFCR's dividend yield?

Lifecore Biomedical Inc. offers a dividend yield of 0.00%.

What is LFCR's Quality Score?

Our AI rates LFCR's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy LFCR?

Our AI Timing Score for LFCR is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does LFCR belong to?

Lifecore Biomedical Inc. is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

Lifecore Biomedical Inc. (LFCR) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-02-28)

LFCR AI Analysis Summary

Our AI summary for LFCR: Lifecore Biomedical Inc. (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of -196.78%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LFCR

Lifecore Biomedical Inc.

USD 4.35

-0.04 (-0.91%) Day Change

Watchlist Portfolio Compare Chart

6.91

D/E

-196.8%

ROE

-18.1%

ROA

0.00%

Div Yield

LIFECORE BIOMEDICAL INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.35 Price -0.04 (-0.91%) Day Change	NEWS SCORE: 91

LFCR, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	4.35
PBV / Sector	7.93 / 10.04
Earning Per Share	-1.08

PE / Sector	N/A / 32.60
PEG or PE/Growth / Sector	N/A / -0.13
Average 1M Daily Value	0.63 M GREAT
Average 1W Daily Value	0.68 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-32.48 / 12.55
NPM Average (%) / Sector	-36.37 / -10.76
NPM Change Average (%) / Sector	-128.50 / 113.68
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-18.13 / 7.68
ROA Average (%) / Sector	-17.07 / 2.97
ROA Change Average (%) / Sector	-133.60 / 111.24
ROE (%) / Sector	-196.78 / 25.75
ROE Average (%) / Sector	-580.94 / 14.00
ROE Change Average (%) / Sector	-826.93 / 377.43
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.52
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.76

Registration Details

Analyze Date	2026-08-05 08:00:28
Symbol	LFCR
Name	LIFECORE BIOMEDICAL INC.
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	37.51 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	164.67 / 10,527.15

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3515 Lyman Boulevard, Chaska, MN, United States, 55318

Phone: 952 368 4300

Website: https://www.lifecore.com

Employees: 382

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.